PMID- 26743526
OWN - NLM
STAT- MEDLINE
DCOM- 20170222
LR  - 20170222
IS  - 1439-4286 (Electronic)
IS  - 0018-5043 (Linking)
VI  - 48
IP  - 4
DP  - 2016 Apr
TI  - Selenium Supplementation Affects Insulin Resistance and Serum hs-CRP in Patients 
      with Type 2 Diabetes and Coronary Heart Disease.
PG  - 263-8
LID - 10.1055/s-0035-1569276 [doi]
AB  - To our knowledge, this study is the first indicating the effects of selenium 
      supplementation on metabolic status of patients with type 2 diabetes mellitus 
      (T2DM) and coronary heart disease (CHD). This study was conducted to evaluate the 
      effects of selenium supplementation on metabolic profiles, biomarkers of 
      inflammation, and oxidative stress of patients with T2DM and CHD. This 
      randomized, double-blind, placebo-controlled trial was performed among 60 
      patients with T2DM and CHD aged 40-85 years. Participants were randomly divided 
      into 2 groups. Group A received 200 mug selenium supplements (n=30) and group B 
      received placebo per day (n=30) for 8 weeks. Fasting blood samples were taken at 
      the beginning of the study and after 8-week intervention to quantify metabolic 
      profiles. After 8 weeks, compared with the placebo, selenium supplementation 
      resulted in a significant decrease in serum insulin levels (- 2.2+/-4.6 vs. 
      + 3.6+/-8.4 muIU/ml, p=0.001), homeostasis model of assessment-insulin resistance 
      (HOMA-IR) (- 0.7+/-1.3 vs. + 0.9+/-2.4, p=0.004), homeostatic model assessment-beta 
      cell function (HOMA-B) (- 7.5+/-17.2 vs. + 15.1+/-34.5, p=0.002) and a significant 
      increase in quantitative insulin sensitivity check index (QUICKI) (+0.01+/-0.03 vs. 
      - 0.01+/-0.03, p=0.02). In addition, patients who received selenium supplements had 
      a significant reduction in serum high-sensitivity C-reactive protein (hs-CRP) 
      (- 1 372.3+/-2 318.8 vs. - 99.8+/-1 453.6 ng/ml, p=0.01) and a significant rise in 
      plasma total antioxidant capacity (TAC) concentrations (+ 301.3+/-400.6 vs. 
      - 127.2+/-428.0 mmol/l, p<0.001) compared with the placebo. A 200 mug/day selenium 
      supplementation among patients with T2DM and CHD resulted in a significant 
      decrease in insulin, HOMA-IR, HOMA-B, serum hs-CRP, and a significant increase in 
      QUICKI score and TAC concentrations.
CI  - (c) Georg Thieme Verlag KG Stuttgart . New York.
FAU - Farrokhian, A
AU  - Farrokhian A
AD  - Department of Cardiology, School of Medicine, Kashan University of Medical 
      Sciences, Kashan, I. R. Iran.
FAU - Bahmani, F
AU  - Bahmani F
AD  - Research Center for Biochemistry and Nutrition in Metabolic Diseases, Kashan 
      University of Medical Sciences, Kashan, I. R. Iran.
FAU - Taghizadeh, M
AU  - Taghizadeh M
AD  - Research Center for Biochemistry and Nutrition in Metabolic Diseases, Kashan 
      University of Medical Sciences, Kashan, I. R. Iran.
FAU - Mirhashemi, S M
AU  - Mirhashemi SM
AD  - Research Center for Biochemistry and Nutrition in Metabolic Diseases, Kashan 
      University of Medical Sciences, Kashan, I. R. Iran.
FAU - Aarabi, M H
AU  - Aarabi MH
AD  - Research Center for Biochemistry and Nutrition in Metabolic Diseases, Kashan 
      University of Medical Sciences, Kashan, I. R. Iran.
FAU - Raygan, F
AU  - Raygan F
AD  - Department of Cardiology, School of Medicine, Kashan University of Medical 
      Sciences, Kashan, I. R. Iran.
FAU - Aghadavod, E
AU  - Aghadavod E
AD  - Research Center for Biochemistry and Nutrition in Metabolic Diseases, Kashan 
      University of Medical Sciences, Kashan, I. R. Iran.
FAU - Asemi, Z
AU  - Asemi Z
AD  - Research Center for Biochemistry and Nutrition in Metabolic Diseases, Kashan 
      University of Medical Sciences, Kashan, I. R. Iran.
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20160107
PL  - Germany
TA  - Horm Metab Res
JT  - Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et 
      metabolisme
JID - 0177722
RN  - 0 (Blood Glucose)
RN  - 0 (Insulin)
RN  - 9007-41-4 (C-Reactive Protein)
RN  - H6241UJ22B (Selenium)
SB  - IM
MH  - Blood Glucose/metabolism
MH  - C-Reactive Protein/*metabolism
MH  - Coronary Artery Disease/*drug therapy/metabolism
MH  - Diabetes Mellitus, Type 2/*drug therapy/metabolism
MH  - Dietary Supplements/analysis
MH  - Double-Blind Method
MH  - Female
MH  - Humans
MH  - Insulin/blood
MH  - *Insulin Resistance
MH  - Male
MH  - Selenium/*administration & dosage
EDAT- 2016/01/09 06:00
MHDA- 2017/02/23 06:00
CRDT- 2016/01/09 06:00
PHST- 2016/01/09 06:00 [entrez]
PHST- 2016/01/09 06:00 [pubmed]
PHST- 2017/02/23 06:00 [medline]
AID - 10.1055/s-0035-1569276 [doi]
PST - ppublish
SO  - Horm Metab Res. 2016 Apr;48(4):263-8. doi: 10.1055/s-0035-1569276. Epub 2016 Jan 
      7.